Chronic Hepatitis C Increases Risk of Death in Patients Admitted to ICU

HCV patients with cirrhosis and severe sepsis face elevated risk of organ failure.
Once the CHC group was stratified by cirrhosis and severe sepsis, there was a lower survival rate compared with the control group of patients with compensated cirrhosis and severe sepsis. Patients in the CHC group with compensated cirrhosis had a greater risk of mortality if they had severe sepsis (aHR = 1.35; p = 0.002).

There was no significant difference found between patients with decompensated cirrhosis and severe sepsis in the CHC group and the control group. These patients with decompensated cirrhosis in the CHC group didn’t have a significant risk of dying compared to the control group.   

Recommended Articles
Study finds a common assortment of reasons for non-initiation of HCV therapy, regardless of patient race or ethnicity.
Managing the risk of hepatitis C and liver disease among infants born to mothers with chronic HCV is a challenge.
Anti-retroviral drug therapy may effectively treat hepatitis C-HIV coinfection.
Antiviral therapies are changing the clinical landscape for the treatment of HCV in developed countries.
Patient access to curative hepatitis C medications remains a challenge.